An induction chemotherapy regimen consisting of cytarabine (Ara-C), daunorubicin and etoposide used for the treatment of childhood acute myeloid leukemia.
As scientists who evolve with technology we treat innovation as a way of life, a life we dedicate to improvement and advancement of Safety, Health and Environment.